Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

0.5371
-0.0072-1.32%
Volume:403.71K
Turnover:214.08K
Market Cap:66.94M
PE:-0.95
High:0.5453
Open:0.5453
Low:0.5206
Close:0.5443
Loading ...

Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial

TIPRANKS
·
10 Jan

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (Xmt-1660)

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

GlobeNewswire
·
10 Jan

Mersana Therapeutics Announces Positive Initial Clinical Data From Phase 1 Clinical Trial of Emiltatug Ledadotin (Xmt-1660); Initiation of Expansion in Triple Negative Breast Cancer

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Inc - Emiltatug Ledadotin Generally Well Tolerated With Differentiated Safety Profile

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

GlobeNewswire
·
10 Jan

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)

TIPRANKS
·
15 Nov 2024

Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)

TIPRANKS
·
14 Nov 2024

Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
14 Nov 2024

Q3 2024 Mersana Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Nov 2024

Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates

Dow Jones
·
14 Nov 2024

Mersana Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

BRIEF-Mersana Therapeutics Provides Business Update And Announces Q3 2024 Financial Results

Reuters
·
13 Nov 2024

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
13 Nov 2024

BRIEF-Mersana Therapeutics Q3 EPS USD -0.09

Reuters
·
13 Nov 2024

Mersana Therapeutics Q3 EPS USD -0.09

THOMSON REUTERS
·
13 Nov 2024